Psyence Biomedical Ltd.
PBM
$1.75
$0.1710.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -167.31% | -167.31% | 96.07% | 96.07% | 284.30% |
| Total Depreciation and Amortization | 44.44% | 44.44% | 1,100.00% | 1,100.00% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 94.72% | 94.72% | -99.39% | -99.39% | -13,151.14% |
| Change in Net Operating Assets | 11.40% | 11.40% | 53.34% | 53.34% | 248.31% |
| Cash from Operations | -33.87% | -33.87% | -63.45% | -63.45% | 4.56% |
| Capital Expenditure | 96.88% | 96.88% | 41.38% | 41.38% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -62,578.13% | -62,578.13% | -68.97% | -68.97% | -- |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | 39.86% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 309.82% | 309.82% | 4,539.34% | 4,539.34% | 1,092.24% |
| Cash from Financing | 159.24% | 159.24% | 331.42% | 331.42% | 216.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.39% | -15.39% | 3,188.42% | 3,188.42% | 264.57% |